항생제 내성 시장 규모, 점유율, 성장 분석 : 질환별, 병원체별, 약제 클래스별, 병원체 유형별, 작용기서별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Antibiotic Resistance Market Size, Share, and Growth Analysis, By Disease (cUTI, CDI ), By Pathogen, By Drug Class, By Pathogen Type, By Mechanism of Action, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1670140
리서치사:SkyQuest
발행일:2025년 02월
페이지 정보:영문 219 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 항생제 내성 시장 규모는 2023년에 101억 6,000만 달러로 평가되며, 2024년 110억 8,000만 달러에서 2032년에는 222억 5,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 9.1%로 성장할 전망입니다.
세계 항생제 내성 시장은 표준 감염 치료의 효과를 위협하는 이 심각한 건강 위기에 대한 우려가 커지면서 크게 성장하고 있습니다. 항생제 남용, 오남용, 의료 환경 전반의 불충분한 감염 예방 조치 등이 이 위기를 부추기는 주요 요인으로 꼽히고 있습니다. 또한 새로운 항생제 파이프라인이 줄어들고 있는 것도 치료의 한계를 악화시키고 있습니다. 그러나 정부, 의료진, 제약사들 사이에서는 이 위기를 극복해야 한다는 인식이 확산되고 있습니다. 민관 파트너십은 항생제 개발의 혁신을 촉진하고 항생제 사용을 최적화하기 위해 항생제 관리 프로그램이 강화되고 있습니다. 또한 교육적 노력을 통해 의료 전문가와 일반 대중의 인식이 향상되고 있습니다. 유전체학 및 단백질체학의 발전은 파지 치료와 같은 새로운 치료법과 함께 항생제 내성에 효과적으로 대처할 수 있는 기회와 과제를 동시에 제시하고 있습니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
항생제 내성 시장 규모 : 질환별
시장 개요
cUTI(복잡성 요로감염증)
CDI(Clostridioides difficile Infection)
ABSSSI(급성 세균성 피부 및 피부 구조 감염증)
HABP(원내 세균성 폐렴)
CABP(지역사회 획득 폐렴)
cIAI(복잡성 복강내 감염증)
BSI(혈류감염증)
항생제 내성 시장 규모 : 병원체별
시장 개요
대장균
폐렴간균
녹농균
황색포도상구균
바우마니
폐렴구균
인플루엔자균
디피실
E.페시움
항생제 내성 시장 규모 : 약제 클래스별
시장 개요
Oxazolidinones
Lipoglycopeptides
Tetracyclines
Combination therapies
Cephalosporins
기타
항생제 내성 시장 규모 : 병원체 유형별
시장 개요
Acinetobacter Baumannii
녹농균
황색포도상구균
폐렴구균
기타
항생제 내성 시장 규모 : 작용기서별
시장 개요
단백질 합성 저해제
세포벽 합성 저해제
RNA 합성 저해제
DNA 합성 저해제
기타
항생제 내성 시장 규모 : 유통 채널별
시장 개요
병원 약국
소매 약국
온라인 약국
항생제 내성 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
기업의 상세
제품 포트폴리오 분석
기업의 부문별 점유율 분석
매출의 전년대비 비교(2022-2024년)
주요 기업 개요
GlaxoSmithKline(GSK)(United Kingdom)
Pfizer(United States)
AbbVie(United States)
Merck & Co.(United States)
Johnson & Johnson(United States)
Novartis(Switzerland)
Roche(Switzerland)
AstraZeneca(United Kingdom)
Eli Lilly and Company(United States)
Bristol-Myers Squibb(United States)
Bayer AG(Germany)
Takeda Pharmaceutical Company(Japan)
Amgen(United States)
Teva Pharmaceutical Industries(Israel)
Abbott Laboratories(United States)
Bausch Health(Canada)
Vaxcyte(United States)
Sumitomo Pharma(Japan)
Fujifilm Holdings Corporation(Japan)
결론과 제안
KSA
영문 목차
영문목차
Global Antibiotic Resistance Market size was valued at USD 10.16 billion in 2023 and is poised to grow from USD 11.08 billion in 2024 to USD 22.25 billion by 2032, growing at a CAGR of 9.1% during the forecast period (2025-2032).
The global antibiotic resistance market is witnessing substantial growth due to escalating concerns surrounding this critical health crisis, which jeopardizes the efficacy of standard infectious disease treatments. Key factors fueling this crisis include antibiotic overuse, misuse, and insufficient infection prevention measures across healthcare settings. Additionally, the diminishing pipeline of new antibiotics exacerbates treatment limitations. However, an increasing acknowledgment among governments, healthcare entities, and pharmaceutical companies underscores the urgency to combat antibiotic resistance. Public-private partnerships are fostering innovation in antibiotic development, while antibiotic stewardship programs are being enhanced to optimize usage. Furthermore, educational initiatives are improving awareness among healthcare professionals and the public. Advancements in genomics and proteomics, alongside emerging treatments like phage therapy, present both challenges and opportunities in addressing antibiotic resistance effectively.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibiotic Resistance market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Antibiotic Resistance Market Segments Analysis
Global Antibiotic Resistance Market is segmented by Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel and region. Based on Disease, the market is segmented into cUTI (Complicated Urinary Tract Infections), CDI (Clostridioides difficile Infection), ABSSSI (Acute bacterial skin and skin structure infections), HABP (Hospital-acquired bacterial pneumonia), CABP (Community-acquired pneumonia), cIAI (Complicated intra-abdominal infection) and BSI (Bloodstream infection). Based on Pathogen, the market is segmented into E. coli, K. pneumoniae, P. aeruginosa, S. aureus, A. baumannii, S. pneumoniae, H. influenzae, C. difficile and E. faecium. Based on Drug Class, the market is segmented into Oxazolidinones, Lipoglycopeptides, Tetracyclines, Combination therapies, Cephalosporins and Others. Based on Pathogen Type, the market is segmented into Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, Streptococcus Pneumoniae and Others. Based on Mechanism of Action, the market is segmented into Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors, DNA Synthesis Inhibitors and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Antibiotic Resistance Market
The surge in infections caused by antibiotic-resistant bacteria underscores the urgent need for the creation of effective treatment solutions. As conventional antibiotics lose their efficacy, there is an increasing demand for novel antibiotics and alternative therapeutic strategies to tackle these resistant strains. This pressing need drives extensive research and development efforts in the field, resulting in the discovery of new drugs and innovative treatment methods to counter antibiotic resistance. Furthermore, the growing public awareness regarding the severe implications of antibiotic resistance has prompted governments, healthcare organizations, and pharmaceutical companies to dedicate resources and invest in initiatives designed to address this critical issue.
Restraints in the Global Antibiotic Resistance Market
The global market for antibiotics faces significant challenges due to the relatively sparse pipeline of new antibiotic candidates in the face of escalating antibiotic resistance threats. The intricate and demanding process of developing novel antibiotics necessitates substantial investment, time, and specialized knowledge. Factors like the exorbitant costs of research and development, regulatory hurdles, and unattractive returns on investment have led to a downturn in antibiotic innovation. This scarcity of new antibiotics impairs the effective treatment of antibiotic-resistant infections, highlighting the pressing need for enhanced initiatives and incentives to promote and accelerate the development of novel antibiotics in the healthcare sector.
Market Trends of the Global Antibiotic Resistance Market
The Global Antibiotic Resistance market is witnessing a significant trend towards the exploration of alternative treatment modalities, driven by the escalating challenge of antibiotic resistance. As conventional antibiotics become less effective, researchers and healthcare professionals are increasingly focusing on innovative solutions such as phage therapy. This cutting-edge approach utilizes bacteriophages to selectively target and eradicate antibiotic-resistant bacteria, effectively addressing the limitations of traditional antibiotics while preserving beneficial microbiota. The growing recognition of the potential of phage therapy, coupled with increased investment in research and development, is set to reshape the landscape of infection management, promising improved patient outcomes in the face of rising resistance.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global Antibiotic Resistance Market Size by Disease & CAGR (2025-2032)
Market Overview
cUTI (Complicated Urinary Tract Infections)
CDI (Clostridioides difficile Infection)
ABSSSI (Acute bacterial skin and skin structure infections)
HABP (Hospital-acquired bacterial pneumonia)
CABP (Community-acquired pneumonia)
cIAI (Complicated intra-abdominal infection)
BSI (Bloodstream infection)
Global Antibiotic Resistance Market Size by Pathogen & CAGR (2025-2032)
Market Overview
E. coli
K. pneumoniae
P. aeruginosa
S. aureus
baumannii
S. pneumoniae
H. influenzae
difficile
E. faecium
Global Antibiotic Resistance Market Size by Drug Class & CAGR (2025-2032)
Market Overview
Oxazolidinones
Lipoglycopeptides
Tetracyclines
Combination therapies
Cephalosporins
Others
Global Antibiotic Resistance Market Size by Pathogen Type & CAGR (2025-2032)
Market Overview
Acinetobacter Baumannii
Pseudomonas Aeruginosa
Staphylococcus Aureus
Streptococcus Pneumoniae
Others
Global Antibiotic Resistance Market Size by Mechanism of Action & CAGR (2025-2032)
Market Overview
Protein Synthesis Inhibitors
Cell Wall Synthesis Inhibitors
RNA Synthesis Inhibitors
DNA Synthesis Inhibitors
Others
Global Antibiotic Resistance Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Antibiotic Resistance Market Size & CAGR (2025-2032)
North America (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
US
Canada
Europe (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
